UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation of Actinium-225 Labeled Minigastrin Analogue [225Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy

Pharmaceutics, 2020-11, Vol.12 (11), p.1088

2020

Volltextzugriff (PDF)

Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [ 177 Lu]Lu-PP-F11N

Pharmaceutics, 2021-12, Vol.13 (12), p.2156

2021

Volltextzugriff (PDF)

Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours

European Journal of Nuclear Medicine, 2008-10, Vol.35 (10), p.1868-1877

2008

Volltextzugriff (PDF)

Signaling Network Response to α-Particle–Targeted Therapy with the 225Ac-Labeled Minigastrin Analog 225Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors

The Journal of nuclear medicine (1978), 2023-06, Vol.64 (6), p.873-879

2023

Volltextzugriff (PDF)

Signaling Network Response to α-Particle-Targeted Therapy with the 225 Ac-Labeled Minigastrin Analog 225 Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors

Journal of Nuclear Medicine, 2023-06, Vol.64 (6), p.873-879

2023

Volltextzugriff (PDF)

Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours

Endocrine-related cancer, 2006-12, Vol.13 (4), p.1203-1211

2006

Volltextzugriff (PDF)

Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma

European journal of nuclear medicine and molecular imaging, 2006-11, Vol.33 (11), p.1273-1279

2006

Volltextzugriff (PDF)

Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies

Seminars in nuclear medicine, 2002-04, Vol.32 (2), p.97-109

2002

Volltextzugriff (PDF)

Influence of Somatostatin Receptor Scintigraphy and CT/MRI on the Clinical Management of Patients with Gastrointestinal Neuroendocrine Tumors: An Analysis in 188 Patients

Digestion, 2003-01, Vol.68 (2-3), p.80-85

2003

Volltextzugriff (PDF)

Imaging Lung Tumors with Peptide-Based Radioligands

Clinical lung cancer, 2003-09, Vol.5 (2), p.119-124

2003

Volltextzugriff (PDF)

Negative correlation between therapeutic success in radioiodine therapy and TcTUs: are TcTUs-adapted dose concepts the only possible answer?

European journal of nuclear medicine and molecular imaging, 2003-08, Vol.30 (8), p.1165-1168

2003

Volltextzugriff (PDF)

Radioimmunotherapy versus traditional, nontargeted forms of systemic cancer treatment

Expert review of anticancer therapy, 2001-12, Vol.1 (4), p.501-505

2001

Volltextzugriff (PDF)

Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies: Radiolabeled peptides in diagnoses and therapy

Seminars in nuclear medicine, 2002, Vol.32 (2), p.97-109

2002

Volltextzugriff (PDF)

Methods for mRNA and Protein Expression Analysis in situ and in vivo

Analysing Gene Expression, 2002, p.703-767

2002

Volltextzugriff (PDF)

Exendin‐4 analogs in insulinoma theranostics

Journal of labelled compounds & radiopharmaceuticals, 2019-08, Vol.62 (10), p.656-672

2019

Volltextzugriff (PDF)

In Vivo Imaging of Local Inflammation: Monitoring LPS-Induced CD80/CD86 Upregulation by PET

Molecular imaging and biology, 2021-04, Vol.23 (2), p.196-207

2021

Volltextzugriff (PDF)

Targeted Radiotherapeutics from 'Bench-to-Bedside'

Chimia, 2020-12, Vol.74 (12), p.939

2020

Volltextzugriff (PDF)

Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy

Endocrinology (Philadelphia), 2000-09, Vol.141 (9), p.3304-3312

2000

Volltextzugriff (PDF)

Evaluation of [99mTc/EDDA/HYNIC0]Octreotide Derivatives Compared with [111In-DOTA0,Tyr3, Thr8]Octreotide and [111In-DTPA0]Octreotide: Does Tumor or Pancreas Uptake Correlate with the Rate of Internalization?

The Journal of nuclear medicine (1978), 2005-09, Vol.46 (9), p.1561-1569

2005

Volltextzugriff (PDF)

Pre‐clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor‐targeted scintigraphy and radionuclide therapy

International journal of cancer, 1998-01, Vol.75 (3), p.406-411

1998

Volltextzugriff (PDF)

Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy

European Journal of Nuclear Medicine, 1997-04, Vol.24 (4), p.368-371

1997

Volltextzugriff (PDF)

Radioimmunotherapy of small-volume disease of metastatic colorectal cancer: Results of a Phase II trial with the iodine-131-labeled humanized anti-carcinoembryonic antigen antibody hMN-14

Cancer, 2002-02, Vol.94 (4), p.1373-1381

2002

Volltextzugriff (PDF)

EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)

European journal of nuclear medicine and molecular imaging, 2014-11, Vol.41 (11), p.2175-2185

2014

Volltextzugriff (PDF)

Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study

The Journal of nuclear medicine (1978), 2020-04, Vol.61 (4), p.520-526

2020

Volltextzugriff (PDF)

Cholecystokinin 2 Receptor Agonist 177 Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study

Journal of Nuclear Medicine, 2020-04, Vol.61 (4), p.520-526

2020

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(28)
Buchkapitel
(1)

Sprache

Englisch
(29)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(15)
Humans
(10)
Animals
(8)
Radiology, Nuclear Medicine & Medical Imaging
(7)
Radionuclide Imaging
(7)
Biological And Medical Sciences
(6)
Medical Sciences
(6)
Tissue Distribution
(6)
Tumors
(6)
Male
(5)
Oncology
(5)
Radioisotopes
(5)
Radiopharmaceuticals - Pharmacokinetics
(5)
Receptors, Somatostatin - Metabolism
(5)
Imaging
(4)
Medicine
(4)
Medicine & Public Health
(4)
Neuroendocrine Tumors - Diagnostic Imaging
(4)
Nuclear Medicine
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluation of Actinium-225 Labeled Minigastrin Analogue [225Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy

Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [ 177 Lu]Lu-PP-F11N

Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours

Signaling Network Response to α-Particle–Targeted Therapy with the 225Ac-Labeled Minigastrin Analog 225Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors

Signaling Network Response to α-Particle-Targeted Therapy with the 225 Ac-Labeled Minigastrin Analog 225 Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors

Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours

Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma

Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies

Influence of Somatostatin Receptor Scintigraphy and CT/MRI on the Clinical Management of Patients with Gastrointestinal Neuroendocrine Tumors: An Analysis in 188 Patients

Imaging Lung Tumors with Peptide-Based Radioligands

Negative correlation between therapeutic success in radioiodine therapy and TcTUs: are TcTUs-adapted dose concepts the only possible answer?

Radioimmunotherapy versus traditional, nontargeted forms of systemic cancer treatment

Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies: Radiolabeled peptides in diagnoses and therapy

Methods for mRNA and Protein Expression Analysis in situ and in vivo

Exendin‐4 analogs in insulinoma theranostics

In Vivo Imaging of Local Inflammation: Monitoring LPS-Induced CD80/CD86 Upregulation by PET

Targeted Radiotherapeutics from 'Bench-to-Bedside'

Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy

Evaluation of [99mTc/EDDA/HYNIC0]Octreotide Derivatives Compared with [111In-DOTA0,Tyr3, Thr8]Octreotide and [111In-DTPA0]Octreotide: Does Tumor or Pancreas Uptake Correlate with the Rate of Internalization?

Pre‐clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor‐targeted scintigraphy and radionuclide therapy

Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy

Radioimmunotherapy of small-volume disease of metastatic colorectal cancer: Results of a Phase II trial with the iodine-131-labeled humanized anti-carcinoembryonic antigen antibody hMN-14

EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)

Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study

Cholecystokinin 2 Receptor Agonist 177 Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study

Suchergebnisse filtern